Interleukin 17 is an important pathogenicity gene in pediatric sepsis

Area of Science:

• Immunology
• Pediatric critical care
• Molecular biology

Background:

• Sepsis is a life-threatening condition characterized by a dysregulated inflammatory response.
• Understanding the molecular mechanisms driving pediatric sepsis is crucial for effective treatment.
• Interleukin 17 (IL-17, also known as IL-17A) is a pro-inflammatory cytokine implicated in various inflammatory diseases.

Purpose of the Study:

• To investigate the role of IL-17A in the development and progression of pediatric sepsis.
• To quantify IL-17A expression levels in a pediatric sepsis model.

Main Methods:

• A neonatal rat model of sepsis was established using intraperitoneal injection of Escherichia coli.
• IL-17A expression in plasma, lung, and liver tissues was analyzed using immunohistochemistry and ELISA.
• A public gene microarray dataset of neonatal sepsis was utilized to validate findings and explore IL-17A functions.

Main Results:

• IL-17A levels in plasma, lung, and liver tissues were significantly elevated in the sepsis group compared to the control group, starting at 4 hours post-infection.
• IL-17A mRNA levels were also found to be significantly higher in pediatric sepsis patients compared to controls.
• Functional enrichment analysis indicated that genes associated with IL-17A in pediatric sepsis are primarily involved in immune response and cell membrane formation.

Conclusions:

• IL-17A expression is upregulated during pediatric sepsis.
• The findings suggest that IL-17A plays a significant role in the pathogenesis of pediatric sepsis.
• IL-17A emerges as a potential therapeutic target for managing pediatric sepsis.